

Australasian Melanoma Conference 2016  
Friday 28 October 2016 - Saturday 29 October 2016  
Sofitel Sydney Wentworth

*As at 19 October 2016 - Program is subject to change*

Friday, 28 October 2016				
	Melbourne/Sydney Room	Perth Room	Brisbane Room	
08:50 - 1030	<i>Plenary Session</i> <i>Sponsored by Amgen</i> <i>Session Chairs:</i> <i>Rick Kefford and Robyn Saw</i>			08:50 - 1030
08:50	Welcome by the Conference Chair <b>Robyn Saw</b> <b>(Melanoma Institute Australia)</b>			08:50
09:00	Mechanisms of resistance to immunotherapies <b>Tom Gajewski</b> <b>(University of Chicago)</b> Sponsored by MSD			09:00
09:30	Immunotherapy. Enhancing response to immunotherapy; lessons from the lab <b>Mark Smyth</b> <b>(QIMR Berghofer Medical Research Institute)</b>			09:30
09:55	Translational research in melanoma <b>Georgina Long</b> <b>(Melanoma Institute Australia)</b>			09:55
10:15	Discussion			10:15
10:30 - 11:00	Morning Tea in Exhibition Area			10:30 - 11:00
11:00 - 12:30	<i>Plenary Session - New Approaches to Melanoma Management: The Laboratory and Clinic Interface</i> <i>Session Chairs:</i> <i>Richard Scolyer and Helen Rizos</i>			11:00 - 12:30
11:00	Understanding responses to therapy: the tissue's the issue, but the scoop's in the poop <b>Jennifer Wargo</b> <b>(MD Anderson Cancer Center)</b>			11:00
11:25	Response and resistance in melanoma <b>Helen Rizos</b> <b>(Macquarie University)</b>			11:25
11:45	Lessons from the Australian Genome Melanoma Project <b>Graham Mann</b> <b>(Westmead Millennium Institute, Melanoma Institute Australia)</b>			11:45
11:55	Targeting cellular pathways in melanoma <b>Keiran Smalley</b> <b>(Moffitt Cancer Center &amp; Research Institute)</b>			11:55
12:10	New approaches to melanoma management: the laboratory and clinic interface <b>Mark Shackleton</b> <b>(Peter MacCallum Cancer Centre)</b>			12:10
12:25	Discussion			12:25
12:30 - 12:40	Melanoma iBook Launch: Jonathan Stretch			12:35 - 12:55

12:40 - 13:30	Lunch in Exhibition Area			12:30 - 13:30
13:30 - 15:15	<b>Hot Topics in Translational Research</b> Session Chairs: Georgina Long and Matt Carlino	<b>Practical Tips in Melanoma Diagnosis and Follow Up</b> Session Chairs: Kerwin Shannon and Pascale Guitera	<b>Oral Presentations</b> Session Chairs: Helen Rizos and Stuart Gallagher	13:30 - 15:15
13:30	Nature and implications of melanoma heterogeneity <b>Mark Shackleton</b> (Peter MacCallum Cancer Centre)		NSAIDs elevate mitochondrial ROS and induce malignant cell death in B16F10 and 4T1 cancer cells <b>Rhys Pritchard</b> (Griffith University)	13:30
			DNA methylation analysis of non-invasive and invasive melanoma cell lines <b>Jyoti Motwani</b> (University of Otago)	13:36
			Reduced DNA repair at CTCF/cohesin binding sites creates functional mutations in melanoma <b>Jason Wong</b> (University of New South Wales)	13:42
13:45	Tumour microenvironment <b>Rod Dunbar</b> (The University of Auckland)	Practical tips in Dermoscopy <b>Scott Menzies</b> (University of Sydney)	HOXA5 regulates PD-L1 expression that is controlled by class I histone deacetylases in cancer cells <b>Chen Chen Jiang</b> (University of Newcastle)	13:48
			Targeting JNK to overcome multi-RTK mediated resistance to RAF-MEK-ERK inhibitors in melanoma <b>Petranel Ferrao</b> (University of Melbourne)	13:54
			Reactive oxygen species dictate the apoptotic response of melanoma cells to TH588 <b>Jiayu Wang</b> (University of Newcastle)	14:00
14:00	Genomic studies in melanoma <b>Richard Scolyer</b> (Melanoma Institute Australia)		The expanding role of microRNAs in melanoma <b>Ms Rikki Brown</b> (Harry Perkins Institute of Medical Research, The University of Western Australia)	14:06
			Apoptosis-regulating long non-coding RNAs in melanoma <b>Yuanyuan Zhang</b> (University of Newcastle)	14:12
			Immune and DNA damage repair gene alterations predict for better outcome in malignant melanoma <b>Mahesh Iddawela</b> (Monash University)	14:18
14:15	Circulating DNA <b>Eiin Gray</b> (Edith Cowan University)		Targeting CDK4 in melanoma: mechanisms of resistance and novel combinational therapies <b>Shatha Abuhammad</b> (The Peter MacCallum Cancer Centre)	14:24

14:30	Germline aberrations and melanoma <b>Nick Hayward</b> (QIMR Berghofer Medical Research Institute)	Biopsy techniques <b>Jonathan Stretch</b> (Melanoma Institute Australia)	Amino acid transporter ASCT2 as a potential therapeutic target for BRAF inhibitor resistant melanoma <b>Nicholas Otte</b> (University of Sydney)	14:30
			Melanoma cells with defect in S phase cell cycle checkpoint are selectively sensitive to single-agent CHK1 inhibitor <b>Zay Yar Oo</b> (Mater Research Institute, The University of Queensland)	14:36
			Repurposing chemotherapy to target methylation, DNA repair and the immune system in melanoma <b>Nikola Bowden</b> (University of Newcastle, Hunter Medical Research Institute)	14:42
14:45	Translational aspects of Immuno-oncology <b>Michele Teng</b> (QIMR Berghofer Medical Research Institute)	Follow Up - why, who and when? <b>Robyn Saw</b> (Melanoma Institute Australia)	Testing the functional significance of pigment heterogeneity in melanotic melanomas <b>Clare Fedele</b> (Peter MacCallum Cancer Centre)	14:48
			Discussion	14:54
15:00	Targeting 'the other' tumor infiltrating immune cells to improve outcome of PD1 <b>Christian Blank</b> (The Netherlands Cancer Institute) Sponsored by BMS	Follow up investigations <b>Omgo Nieweg</b> (Melanoma Institute Australia)		
15:15 - 15:45	Afternoon Tea in Exhibition Area			15:15 - 15:45
15:45 - 17:00	<b>Melanoma Prevention</b> Session Chairs: <i>Michael Henderson and Peter Soyer</i>	<b>Oral Presentations</b> Session Chairs: <i>Michele Teng and Nick Hayward</i>	<b>Oral Presentations</b> Session Chairs: <i>James Wilmott and Victoria Mar</i>	15:45 - 17:00
15:45	Melanoma prevention <b>David Whiteman</b> (QIMR Berghofer Medical Research Institute)	Contribution of alternate survival pathways in melanoma responses to combination BRAF/MEK inhibition <b>Mal Irvine</b> (Macquarie University)	Novel targets for vitamin D in melanoma <b>Arthur Shariev</b> (University of Sydney)	15:45
		Identification of survival pathways In BRAF and Nras wild-type melanomas <b>Zizhen Ming</b> (Macquarie University)	Nicotinamide for skin cancer chemoprevention: effects on tumour immune cells and melanoma biology <b>Rashi Minocha</b> (University of Sydney, Royal Prince Alfred Hospital)	15:51
		Defining the mode of melanoma heterogeneity and drug sensitivity by real-time cell cycle imaging <b>Nikolas Haass</b> (The University of Queensland)	The role of DNA repair signaling in the survival and progression of melanoma <b>Mariana Brocardo</b> (Macquarie University)	15:57

16:10	The dark side of sun protection: autoimmunity and UV <b>Scott Byrne</b> (University of Sydney)	Microfluidic-based isolation and molecular detection of circulating tumour cells (CTCs) from metastatic melanoma patients <b>Carlos Aya-Bonilla</b> (Edith Cowan University)	Cyclin D1 Polymorphism and risk for melanoma <b>Svetlana Rubakovic</b> (Genetic Research Institute of the Desert)	16:03
		The isolation of intact melanoma quiescent cells <b>Ting La</b> (University of Newcastle)	Use of support services by high-risk primary melanoma patients in Queensland <b>Lena Von Schuckmann</b> (QIMR Berghofer Institute of Medical Research)	16:09
		Biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD1 Immunotherapy <b>Tuba Nur Gide</b> (Melanoma Institute Australia, University of Sydney)	Incidence of residual melanoma or local metastasis In wide local excision specimens after 'complete' excision of primary cutaneous melanomas <b>Louise Jackett</b> (Melanoma Institute Australia, University of Sydney, Royal Prince Alfred Hospital)	16:15
		Genome-wide methylation response to combined treatment of melanoma with decitabine and carboplatin <b>Timothy Budden</b> (Hunter Medical Research Institute, University of Newcastle)	The application of the smart scoring technique to the mapping of lentigo maligna prior to surgery: a case series of five patients <b>Phoebe Star</b> (Melanoma Institute Australia)	16:21
		SPOP confers resistance to BRAF inhibition in BRAFV600E melanoma <b>Zsuzsanna Nagy</b> (Macquarie University)	Clinicopathological associations of NF1 mutant melanomas <b>Louise Jackett</b> (Melanoma Institute Australia, University of Sydney, Royal Prince Alfred Hospital)	16:27
		Melanoma In Iran: a retrospective 10-year study <b>Samira Ferdosi</b> (Cancer Institute of Imam Khomeini Hospital)	Unusual mutation signatures identified by whole genome sequencing in acral and cutaneous melanomas <b>Robert Rawson</b> (Melanoma Institute of Australia)	16:33
16:35	Nicotinamide chemoprevention <b>Diona Damian</b> (University of Sydney)	Rapid autopsy reveals dominant acquisition of large-scale chromosomal changes in end-stage melanoma <b>Ismael A. Vergara</b> (Peter MacCallum Cancer Centre)	Histopathologic and siascopic correlation of pigmented skin lesions in rural NSW: a two year prospective study <b>Sujatha Fernando</b> (Southern IML)	16:39
		Discussion	Discussion	16:45
16:50	Discussion	Discussion	Discussion	16:45
17:00 - 18:30	Welcome Reception with drinks and canapés (Sofitel Wentworth Sydney)			17:00 - 18:30

**Australasian Melanoma Conference 2016**  
**Friday 28 October 2016 - Saturday 29 October 2016**  
**Sofitel Sydney Wentworth**

*As at 19 October 2016 - Program is subject to change*

Saturday, 29 October 2016				
	Melbourne/Sydney Room	Perth Room	Brisbane Room	
07:30 - 08:45	<b>BMS Sponsored Breakfast Symposium: Dr Christian Blank</b> (Breakfast served at 0730; session commences 0745)			07:30 - 08:45
09:00 - 10:30	<i>Plenary Session</i> Session Chairs: <i>John Thompson and Georgina Long</i>			09:00 - 10:30
09:00	Atypical melanocytic lesions <b>Vernon Sondak</b> (Moffitt Cancer Center & Research Institute)			09:00
09:25	Resection in the age of systemic therapies <b>Jennifer Wargo</b> (MD Anderson Cancer Center)			09:25
09:50	Systemic therapy in melanoma - what do we know and where to next? <b>Grant Mcarthur</b> (Peter MacCallum Cancer Centre)			09:50
10:15	Discussion			10:15
10:30 - 11:00	<b>Morning Tea in Exhibition Area</b>			10:30 - 11:00
11:00 - 12:30	<i>Advances in Melanoma Diagnosis</i> Session Chairs: <i>Diona Damian and Hsien Chan</i>	<i>Drug Therapy for Melanoma - Pushing the Boundaries</i> Session Chairs: <i>Rick Kefford</i>	<i>Oral Presentations</i> Session Chairs: <i>Robyn Saw and David Gyorki</i>	11:00 - 12:30
11:00	Is pathology the gold standard for diagnosis of melanoma: does it glitter? <b>Richard Scolyer</b> (Melanoma Institute Australia)	Immunotherapy for melanoma <b>Christian Blank</b> (The Netherlands Cancer Institute) Sponsored by BMS	Invasive melanoma mortality to incidence ratios by local health district in New South Wales 2007-2011 <b>Jeffrey Keir</b> (University of Queensland)	11:00
			Multiple lymphatic field drainage in cutaneous melanoma. <b>Tariq Cachalia</b> (Central Coast Area Health Service)	11:06
			Triangular intermuscular space sentinel nodes in melanoma and their relation to the axilla <b>Trine Schoenfeldt</b> (Melanoma Institute Australia)	11:12
			Lymphadenectomy for stage III melanoma <b>Rahul Jayakar</b> (Hutt Valley District Health Board)	11:18

11:20	Amelanotic melanoma and BCC <b>Victoria Mar</b> (The Alfred Hospital)	Targeted therapies <b>Grant McArthur</b> (Peter MacCallum Center)	Can patients with positive sentinel lymph nodes be spared a complete dissection? <b>Thilina Bandara</b> (Westmead Hospital)	11:24
			Subungual melanoma – management in the modern era <b>Gamze Aksakal</b> (Peter MacCallum Cancer Centre)	11:30
			Simulation modeling methods to quantify radiation risk from repeated CT imaging for asymptomatic patients with AJCC stage III melanoma <b>Anna Martin</b> (University of Sydney)	11:36
11:40	Dermoscopy Pearls and quiz <b>Peter Soyer</b> (University of Queensland)	Adjuvant systemic therapy in melanoma <b>Alex Menzies</b> (Melanoma Institute Australia)	Fear of new or recurrent melanoma after treatment for localised melanoma <b>Katy Bell</b> (University of Sydney)	11:42
			Systematic review and meta analysis of utility-based quality of life in melanoma <b>Anh Tran</b> (University of Sydney)	11:48
			Evaluating the efficacy of a skin cancer prevention mobile application amongst students aged 7 to 13 in Australia and the United States <b>Misha Kaura</b> (University of Sydney)	11:54
11:55		Neo adjuvant therapy for melanoma: are we there yet? <b>Georgina Long</b> (Melanoma Institute Australia)	New technologies in skin cancer prevention <b>Elke Hacker</b> (Queensland University of Technology)	12:00
			Clinical and molecular characteristics and metastatic pathways of patients with cutaneous melanoma <b>Nikki Adler</b> (Monash University)	12:06
			Discussion	12:12
12:10	Systemic therapy in populations of unmet need - uveal and mucosal melanoma <b>Matteo Carlino</b> (Westmead Hospital)			
	12:25	Discussion		
12:30 - 13:30	Lunch in Exhibition Area			12:30 - 13:30
12:40 - 13:30	Pierre Fabre Sponsored Lunch Symposium: Associate Professor Pascale Guitera			12:30 - 13:30

13:30 - 15:00	<b>Surgical Conundrums in the Modern Era</b> <i>Session Chairs:</i> <i>Richard Martin and Omgo Nieweg</i>	<b>Confocal Microscopy Session</b> <i>Session Chairs:</i> <i>Victoria Mar and Jonathan Stretch</i>	<b>Oral Presentations</b> <i>Session Chairs:</i> <i>Alex Menzies and Angela Hong</i>	13:30 - 15:00
13:30	Optimising sentinel node assessment: who, how and how much? <b>David Gyorki</b> <b>(Peter MacCallum Cancer Centre)</b>	Why use confocal microscopy? <b>Pascale Guitera</b> <b>(Melanoma Institute Australia)</b>	IMAGO: Enhancing multidisciplinary team care through knowledge transfer <b>Sarah-Jane Schramm</b> <b>(University of Sydney, Melanoma Institute Australia),</b> <b>Serigne Lo</b> <b>(Melanoma Institute Australia)</b>	13:30
13:35		Confocal for beginners <b>Caterina Longo</b> <b>(Hospital Arcispedale Santa Maria Nuova-IRCCS)</b>	Meta-analysis of phase 2 trials in metastatic uveal Melanoma <b>Anthony Joshua</b> <b>(Kingshorn Cancer Centre, Princess Margaret Cancer Centre)</b>	13:36
13:45	In transit disease <b>Mark Faries</b> <b>(John Wayne Cancer Institute)</b>		Can melanoma treatment be guided by a panel of predictive and prognostic microRNA biomarkers? <b>Mitchell Stark</b> <b>(University of Queensland)</b>	13:42
14:00	Nodal disease <b>Michael Henderson</b> <b>(Peter MacCallum Cancer Centre)</b>	Correlation between confocal and pathology for naevi <b>Helena Collgros</b> <b>(Royal Prince Alfred Hospital)</b>	Plasma biomarkers as predictors of patient response to combined anti-CTLA4 and anti-PD1 in melanoma <b>Su Yin Lim</b> <b>(Macquarie University)</b>	13:48
13:45			Molecular analysis of a series of acral melanomas in Singapore <b>Inny Busmanis</b> <b>(Singapore General Hospital)</b>	13:54
14:00			Survival outcomes following resection of Stage IV melanoma <b>Stefanos Kanatsios</b> <b>(University of Melbourne)</b>	14:00
14:06			Outcomes following cessation of BRAF +/- Mek inhibition after achieving complete response <b>Christina Girgis</b> <b>(Westmead Hospital)</b>	14:06
14:12			Anti-PD1 therapy in patients with metastatic melanoma – a single centre experience <b>Estella Janz-Robinson</b> <b>(ACT Health)</b>	14:12
14:15			Safety and efficacy of PD1 agents in elderly population <b>Dr Rajat Rai</b> <b>(Melanoma Institute Australia)</b>	14:18

14:20	How I treat brain metastases <b>Brindha Shivalingam</b> (Royal Prince Alfred Hospital)	Correlation between confocal and pathology for melanoma <b>Caterina Longo</b> (Hospital Arcispedale Santa Maria Nuova-IRCCS)	Efficacy of anti-PD1 therapy in patients with melanoma brain metastases <b>John Park</b> (Westmead Hospital)	14:24
14:35	The new staging guidelines <b>John Thompson</b> (Melanoma Institute Australia)		Leptomeningeal melanoma – a case series in the era of modern systemic therapy <b>Malmaruha Arasaratnam</b> (Royal North Shore Hospital)	14:30
14:45		The challenge of amelanotic melanoma <b>Pascale Guitera</b> (Melanoma Institute Australia)	Survival and prognostic factors of metastatic melanoma patients with brain metastases <b>Martin Tio</b> (Royal North Shore Hospital)	14:36
14:50			Discussion	Five high quality Australian trials are helping define the role of radiotherapy in melanoma <b>Gerald Fogarty</b> (ANZMTG, Melanoma Institute Australia)
14:50			Update on clinical trials - ANZMTG <b>Elizabeth Paton</b> (ANZMTG)	14:48
15:00 - 15:30	Afternoon Tea in Exhibition			15:00 - 15:30
15:30 - 17:15	<i>Challenging Situations in Melanoma Care</i> Session Chairs: <i>Grant McArthur and Matt Carlino</i>		<i>Margin Control</i> Session Chair: <i>Diona Damian</i>	15:30 - 17:15
15:30	Paediatric melanoma <b>Vernon Sondak</b> (Moffitt Cancer Center & Research Institute)		Confocal and non melanocytic lesions <b>Caterina Longo</b> (Hospital Arcispedale Santa Maria Nuova-IRCCS)	15:30
15:50	Side effects of systemic therapy <b>Alex Guminski</b> (University of Sydney)		A new technique <b>Caterina Longo</b> (Hospital Arcispedale Santa Maria Nuova-IRCCS)	15:50
16:05	Managing cutaneous side effects of melanoma treatment <b>Pablo Fernandez-Penas</b> (Westmead Hospital)		New technology: In practice and in the future <b>Pascale Guitera</b> (Melanoma Institute Australia)	16:10
16:15	Supportive care - how we can do better <b>Melanie Lovell</b> (University of Sydney)			16:30
16:30	Saturday MDT: Three challenging cases with expert panel: what should I do? <b>Alex Menzies</b> (Melanoma Institute Australia)			17:10
17:10	Closing Address			